buy on dips to be followed for one month

Aurobindo Pharma Limited is a pharmaceutical company engaged in the development, manufacturing and marketing of generic medicines, active pharmaceutical ingredients (APIs) and specialty products. Its business has a significant international presence, particularly in the United States and Europe. The company's long-term growth depends on product launches, manufacturing efficiency, regulatory compliance, international demand and its ability to maintain healthy operating margins. Aurobindo Pharma reported a strong Q1 FY27 performance for the quarter ended June 2026. Financial indicator Q1 FY27 Revenue from operations ₹9,150 crore Year-on-year revenue growth 16.3% Net profit ₹1,033 crore Year-on-year profit growth 25.2% Operating EBITDA margin Approximately 21% The stock is trading below its recent 52-week high of approximately ₹1,740. The following are indicative technical zones for monitoring, not guaranteed support or resistance levels. Price zone Technical interpretation ₹1,700–1,740 Major resistance zone ₹1,660–1,680 Near-term price zone ₹1,600–1,620 Potential support zone ₹1,550–1,580 Important lower support zone Below ₹1,550 Further weakness may emerge These zones are provisional and should be verified against the latest daily chart, volume and closing prices before taking a trading decision.